1. 1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study. (26th November 2018) Authors: Mische, Sarah; Orenstein, Robert; Dubberke, Erik R; Khanna, Sahil; Hecht, Gail; Dupont, Herbert; Lee, Christine; Blount, Ken Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Infection by Bacterial Pathogens Expressing Type III Secretion Decreases Luciferase Activity: Ramifications for Reporter Gene Studies. (September 2000) Authors: Savkovic, Suzana D.; Koutsouris, Athanasia; Wu, Gary; Hecht, Gail Journal: Biotechniques Issue: Volume 29:Number 3(2000) Page Start: 514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Microbiome Profile is Distinct in Patients with Successful Response to Microbiota-Based Drug RBX2660 Relative to Placebo Responders. (4th October 2017) Authors: Dubberke, Erik R; Orenstein, Robert; Lee, Christine; Khanna, Sahil; Hecht, Gail; Gerding, Dale N; Blount, Ken; Shannon, Bill Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S538 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent Clostridium difficile, and May Rehabilitate Patient Microbiomes: Open Label Trial Results. (4th October 2017) Authors: Orenstein, Robert; Dubberke, Erik R; Khanna, Sahil; Hecht, Gail; Dupont, Herbert; Lee, Christine; Blount, Ken; Carter, Sharina Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S535 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. (29th March 2018) Authors: Dubberke, Erik R; Lee, Christine H; Orenstein, Robert; Khanna, Sahil; Hecht, Gail; Gerding, Dale N Journal: Clinical infectious diseases Issue: Volume 67:Number 8(2018) Page Start: 1198 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S1264 Evaluation of Gender Disparity in Gastroenterology Societies' Leadership. (October 2020) Authors: Trieu, Judy A.; Venu, Mukund; Shokoohi, Susanne; Wakade, Zuie; Asamoah, Nikiya; Hecht, Gail Journal: American journal of gastroenterology Issue: Volume 115:Supplement(2020)ACG Annual Meeting Abstracts 1 Page Start: S634 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. S157 24-Month Sustained Clinical Response and Safety of RBX2660 in Participants With Recurrent Clostridioides difficile Infection: Subgroup Analysis. (October 2022) Authors: Lee, Christine; Hecht, Gail; Tillotson, Glenn; Harvey, Adam; Ng, Samson; Ando, Masakazu; LaPlante, Kerry; Dubberke, Erik R. Other Names: Orenstein Robert presenter. Journal: American journal of gastroenterology Issue: Volume 117:Number 10(2022)supplement 10S Page Start: e112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. There Is No Association Between Patient Outcomes and Demographics in an Open‐Label Safety and Efficacy Study of RBX2660, a Microbiota‐Based Drug for RecurrentClostridium difficileInfection: 139. (October 2017) Authors: Ray, Arnab; Hecht, Gail; Orenstein, Robert; Lee, Christine; Dubberke, Erik; Khanna, Sahil; Blount, Ken Journal: American journal of gastroenterology Issue: Volume 112(2017)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗